<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Braz J Med Biol Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Braz. J. Med. Biol. Res</journal-id>
      <journal-title-group>
        <journal-title>Brazilian Journal of Medical and Biological Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0100-879X</issn>
      <issn pub-type="epub">1414-431X</issn>
      <publisher>
        <publisher-name>Associa&#xE7;&#xE3;o Brasileira de Divulga&#xE7;&#xE3;o Cient&#xED;fica</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24770567</article-id>
      <article-id pub-id-type="pmc">4086180</article-id>
      <article-id pub-id-type="doi">10.1590/1414-431X20143830</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Investigation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Successful domino liver transplantation in maple syrup
urine disease using a related living donor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Feier</surname>
            <given-names>F.H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miura</surname>
            <given-names>I.K.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fonseca</surname>
            <given-names>E.A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Porta</surname>
            <given-names>G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pugliese</surname>
            <given-names>R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Porta</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schwartz</surname>
            <given-names>I.V.D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Margutti</surname>
            <given-names>A.V.B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Camelo</surname>
            <given-names>J.S.</given-names>
            <suffix>Jr</suffix>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamaguchi</surname>
            <given-names>S.N.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taveira</surname>
            <given-names>A.T.</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Candido</surname>
            <given-names>H.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Benavides</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Danesi</surname>
            <given-names>V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guimaraes</surname>
            <given-names>T.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kondo</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chapchap</surname>
            <given-names>P.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seda</surname>
            <given-names>J.</given-names>
            <suffix>Neto</suffix>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label> Hospital S&#xED;rio-Liban&#xEA;s, Departamento de Hepatologia e Transplante
Hep&#xE1;tico, S&#xE3;o Paulo, SP, Brasil, Departamento de Hepatologia e Transplante Hep&#xE1;tico,
Hospital S&#xED;rio-Liban&#xEA;s, S&#xE3;o Paulo, SP, Brasil</aff>
        <aff id="aff2"><label>2</label> Universidade Federal do Rio Grande do Sul, Departamento de Gen&#xE9;tica,
Porto Alegre, RS, Brasil, Departamento de Gen&#xE9;tica, Universidade Federal do Rio
Grande do Sul, Porto Alegre, RS, Brasil</aff>
        <aff id="aff3"><label>3</label> Hospital de Cl&#xED;nicas de Porto Alegre, Departamento de Gen&#xE9;tica
M&#xE9;dica, Porto Alegre, RS, Brasil, Departamento de Gen&#xE9;tica M&#xE9;dica, Hospital de
Cl&#xED;nicas de Porto Alegre, Porto Alegre, RS, Brasil</aff>
        <aff id="aff4"><label>4</label> Universidade de S&#xE3;o Paulo, Faculdade de Medicina de Ribeir&#xE3;o Preto,
Departamento de Pediatria, Ribeir&#xE3;o Preto, SP, Brasil, Departamento de Pediatria,
Faculdade de Medicina de Ribeir&#xE3;o Preto, Universidade de S&#xE3;o Paulo, Ribeir&#xE3;o Preto,
SP, Brasil</aff>
        <aff id="aff5"><label>5</label> Hospital S&#xED;rio-Liban&#xEA;s, Departamento de Nutri&#xE7;&#xE3;o, S&#xE3;o Paulo, SP,
Brasil, Departamento de Nutri&#xE7;&#xE3;o, Hospital S&#xED;rio-Liban&#xEA;s, S&#xE3;o Paulo, SP, Brasil</aff>
        <aff id="aff6"><label>6</label> Universidade Estadual do Amazonas, Departamento de Hepatologia,
Manaus, AM, Brasil, Departamento de Hepatologia, Universidade Estadual do Amazonas,
Manaus, AM, Brasil</aff>
      </contrib-group>
      <author-notes>
        <corresp>Correspondence: J. Seda Neto, Hospital S&#xED;rio-Liban&#xEA;s/Hospital A.C. Camargo, Rua
Barata Ribeiro, 414, Conjunto 65, 01308-000 S&#xE3;o Paulo, SP, Brasil, +55-11-3231-0900.
E-mail: <email>joaoseda@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>5</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <volume>47</volume>
      <issue>6</issue>
      <fpage>522</fpage>
      <lpage>526</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>4</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Maple syrup urine disease (MSUD) is an autosomal recessive disease associated with
high levels of branched-chain amino acids. Children with MSUD can present severe
neurological damage, but liver transplantation (LT) allows the patient to resume a
normal diet and avoid further neurological damage. The use of living related donors
has been controversial because parents are obligatory heterozygotes. We report a case
of a 2-year-old child with MSUD who underwent a living donor LT. The donor was the
patient's mother, and his liver was then used as a domino graft. The postoperative
course was uneventful in all three subjects. DNA analysis performed after the
transplantation (sequencing of the coding regions of <italic>BCKDHA</italic>,
<italic>BCKDHB</italic>, and <italic>DBT</italic> genes) showed that the MSUD
patient was heterozygous for a pathogenic mutation in the <italic>BCKDHB</italic>
gene. This mutation was not found in his mother, who is an obligatory carrier for
MSUD according to the family history and, as expected, presented both normal clinical
phenotype and levels of branched-chain amino acids. In conclusion, our data suggest
that the use of a related donor in LT for MSUD was effective, and the liver of the
MSUD patient was successfully used in domino transplantation. Routine donor
genotyping may not be feasible, because the test is not widely available, and, most
importantly, the disease is associated with both the presence of allelic and locus
heterogeneity. Further studies with this population of patients are required to
expand the use of related donors in MSUD.</p>
      </abstract>
      <kwd-group>
        <kwd>Heterozygous donor</kwd>
        <kwd>Metabolic disease</kwd>
        <kwd>Branched-chain ketoacid dehydrogenase mutation</kwd>
        <kwd>Leucine</kwd>
        <kwd>Genotype</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="1"/>
        <ref-count count="20"/>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Maple syrup urine disease (MSUD) is an autosomal recessive metabolic disorder that
results in decreased activity of the branched-chain ketoacid dehydrogenase (BCKDH)
complex, leading to accumulation of the branched-chain amino acids (BCAA) leucine,
isoleucine, and valine. MSUD presents locus heterogeneity, which means that it can be
caused either by mutations in <italic>BCKDHA</italic>, <italic>BCKDHB</italic>, or
<italic>DBT</italic> genes or by allelic heterogeneity (<xref rid="B01" ref-type="bibr">1</xref>). In developing countries, where there is no neonatal screening
for MSUD in public healthcare, the diagnosis is usually based on a combination of
clinical (irritability, poor feeding, lethargy, intermittent apnea) and biochemical
findings in which high levels of leucine, isoleucine, or valine are detected in serum by
quantitative methods such as high-performance liquid chromatography, but the other amino
acids are in the normal or low ranges. Measurement of alloisoleucine, BCKDH activity,
and DNA analysis are not widely available.</p>
      <p>Leucine, isoleucine, and valine are toxic to the central nervous system and can produce
different grades of neuropathy, or even death, if the disease is not treated (<xref rid="B02" ref-type="bibr">2</xref>). Because the liver is responsible for around 15%
of enzymatic BCKDH production, liver transplantation (LT) can restore some enzymatic
activity in MSUD patients (<xref rid="B03" ref-type="bibr">3</xref>). Indeed, a decrease
in leucine concentration has been observed hours after performing LT in patients with
MSUD, using deceased donors (<xref rid="B03" ref-type="bibr">3</xref>). Since livers
from MSUD patients are structurally normal, they are a source of grafts for domino liver
transplantation (DLT) (<xref rid="B04" ref-type="bibr">4</xref>). This case report
describes a successful DLT in which the donor was the mother of the recipient with
MSUD.</p>
    </sec>
    <sec sec-type="methods">
      <title>Patients and Methods</title>
      <sec>
        <title>Patient 1</title>
        <p>Patient 1, a 2-year-old boy, son of a nonconsanguineous couple, was diagnosed with
the classic form of MSUD 5 days after birth following an uneventful prenatal period.
He was discharged from the hospital at 48 h of life. He was exclusively breastfed
after being discharged. On day 5 the patient presented lethargy and on day 7 he was
in a coma, and was admitted to the intensive care unit (ICU). His first sibling had
been diagnosed with MSUD during the neonatal period and died 2 months after birth. In
the ICU, the BCAA levels of Patient 1 were leucine, 904 &#xB5;M [normal reference values
(NRV): 47-155 &#xB5;M]; isoleucine, 31 &#xB5;M (NRV: 31-86 &#xB5;M); and valine, 406 &#xB5;M (NRV: 64-294
&#xB5;M). A restricted diet (leucine tolerance 55 mg&#xB7;kg<sup>-1</sup>&#xB7;day<sup>-1</sup>) was
started in the ICU. During his first year of life, the patient had three ICU
admissions for respiratory infections associated with high levels of leucine, and
because of difficulty swallowing, a gastrostomy tube was inserted to provide
nutrition. At the age of 12 months and weighing 9800 <italic>g</italic>
(<italic>z</italic> score height/age: -1.49), the patient was referred to our
group for evaluation for LT. At this point, we had no information about his genotype.
During evaluation for transplantation, he was found to present significant
neurological and psychomotor disability, axial hypotonia, and seizures. His
pretransplantation plasma leucine level was 846.2 &#xB5;M (<xref ref-type="fig" rid="f01">Figure 1</xref>), and his pediatric end-stage liver disease (PELD) score was
-1.</p>
        <fig id="f01" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <title>
<italic>A</italic>, Pre- and post-transplantation branched-chain amino acid
(BCAA) levels of the recipient with maple syrup urine disease.
<italic>B</italic>, Molar relationship between BCAAs (log<sub>10</sub>). LT:
liver transplantation.</title>
          </caption>
          <graphic xlink:href="1414-431X-bjmbr-47-06-00522-gf001"/>
        </fig>
      </sec>
      <sec>
        <title>Patient 2</title>
        <p>Patient 2 was a 33-month-old boy with biliary atresia who underwent a
portoenterostomy. He had portal hypertension (esophageal varices) and also presented
repeated episodes of cholangitis. Pretransplantation laboratory test results were
hemoglobin, 9.7 mg/dL; total bilirubin (TB), 12.8 mg/dL; sodium, 138 mEq/L; urea, 22
mg/dL; and creatinine, 0.26 mg/dL. He weighed 13 kg, his <italic>z</italic> score
height/age was -1.73, and PELD score was 11. He was selected to receive the DLT
because of ABO blood type compatibility and size match.</p>
      </sec>
      <sec>
        <title>Living donor</title>
        <p>The donor for Patient 1 was his 41-year-old mother. She had neither a previous record
of metabolic decompensation nor a history of comorbidities, except for a previous
laparoscopic cholecystectomy. Because she had two siblings with MSUD, she was assumed
to be a heterozygote (i.e., an obligatory carrier) with a normal phenotype. Indeed,
her preoperative aminoacidogram was normal; with valine, 161.5 &#xB5;M (NRV: 130-307 &#xB5;M);
leucine, 96.5 &#xB5;M (NRV: 65-179 &#xB5;M); and isoleucine, 38.3 &#xB5;M (NRV: 33-97 &#xB5;M). All the
patients or their parents gave informed consent and the study was approved by the
hospital's Ethics Committee.</p>
      </sec>
      <sec>
        <title>Genotype</title>
        <p>The decision to perform the DLT was based on phenotypic characteristics of both the
donor and the MSUD recipient. Genotyping was not available at the time of the
transplantation. Afterward, it was possible to include both the donor and Patient 1
in a national research study aimed at characterizing MSUD mutations (the Brazilian
MSUD Network), with the approval of the Hospital de Cl&#xED;nicas de Porto Alegre Ethics
Committee. There was no sample from the father for genotyping.</p>
        <p>DNA was extracted from peripheral blood leukocytes of the mother and the patient, and
all exon and exon-intron boundaries of <italic>BCKDHA</italic>,
<italic>BCKDHB</italic>, and <italic>DBT</italic> were analyzed by direct
sequencing to identify possible mutations.</p>
        <p>The mutation found in the MSUD patient and his mother is reported in <xref ref-type="table" rid="t01">Table 1</xref>.</p>
        <p>
<table-wrap id="t01" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-47-06-00522-gt001"/></table-wrap>
</p>
      </sec>
      <sec>
        <title>Postoperative courses</title>
        <p>The living donor had an uneventful postoperative course and was discharged from the
hospital 5 days after the procedure. She was on an unrestricted diet and experienced
no adverse events during follow-up (13 months after the donation).</p>
        <p>Patient 1 remained stable throughout and after the transplantation. On postoperative
day (POD) 1, he was started on a diet of restricted leucine intake (70
mg&#xB7;kg<sup>-1</sup>&#xB7;day<sup>-1</sup>) via the gastrostomy tube. This intake was
subsequently increased from 70 to 156 mg&#xB7;kg<sup>-1</sup>&#xB7;day<sup>-1</sup>. An
aminoacidogram was performed on POD 2 and his plasma leucine level was 210 &#xB5;M (NRV:
&lt;205 &#xB5;M). He experienced an episode of acute cellular rejection on POD 7. He was
discharged on POD 17 and readmitted 40 days later due to a cytomegalovirus infection.
Patient 1 did not present any metabolic decompensation after the transplantation.
Laboratory test results 13 months after the transplantation were: aspartate
aminotransferase (AST), 51 IU/L; alanine aminotransferase (ALT), 42 IU/L;
gamma-glutamyltransferase (GGT), 82 IU/L, and TB, 0.2 mg/dL. <xref ref-type="fig" rid="f01">Figure 1</xref> shows the variations in BCAA levels pre- and
post-transplantation.</p>
        <p>Neurologically, this patient showed significant improvement; the hypotonia
diminished, and he was able to stand with assistance. He did not experience seizures.
However, he continued to have difficulty swallowing and still used a gastrostomy
tube.</p>
        <p>Patient 2 remained stable after the transplantation and was discharged from the
hospital on POD 18. Laboratory test results 13 months post-transplantation were: AST,
41 IU/L; ALT, 24 IU/L; GGT, 11 IU/L; and TB, 0.35 mg/dL. An aminoacidogram performed
8 months post-transplantation indicated normal levels of leucine (122 &#xB5;M), isoleucine
(73 &#xB5;M), and valine (225 &#xB5;M).</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>LT was discovered as a treatment for MSUD after transplantations had been performed for
nonmetabolic reasons in the first patients (<xref rid="B05" ref-type="bibr">5</xref>).
These patients achieved good metabolic control and their leucine levels normalized in
the immediate postoperative period. After that, the Pittsburgh Group reported the
results for 10 additional patients transplanted for MSUD with whole livers. They
achieved 100% patient and graft survival after a median follow-up of 14 months. All
patients were on normal diets (<xref rid="B03" ref-type="bibr">3</xref>). In 2012,
Mazariegos et al. (<xref rid="B06" ref-type="bibr">6</xref>) expanded their group's
experience and reported on 37 patients transplanted for MSUD along with 17 patients from
the United Network for Organ Sharing database. Only one patient underwent living donor
LT. Based on this experience, the authors argue that LT provides adequate metabolic
control with normal diet and better neurological development and eliminates the risk of
sudden brain edema and death (<xref rid="B03" ref-type="bibr">3</xref>,<xref rid="B06" ref-type="bibr">6</xref>,<xref rid="B07" ref-type="bibr">7</xref>). The
efficacy of LT for MSUD indicates that introducing about 10% of normal BCKDH activity on
a whole body basis is sufficient to maintain peripheral amino acid homeostasis. The
transplanted liver in the MSUD recipient becomes responsible for over 90% degradation of
BCAAs, resulting in normal plasma leucine levels (<xref rid="B08" ref-type="bibr">8</xref>). LT not only eliminates high and variable BCAA levels, but also protects
children from essential amino acid deficiencies, which may be equally important in the
optimization of physical and neurological development.</p>
      <p>Livers from MSUD patients can be used for DLT. Domino livers were first considered as
marginal grafts because the disease could manifest in the domino recipient (<xref rid="B09" ref-type="bibr">9</xref>). However, recipients of liver grafts from MSUD
donors will probably not develop protein intolerance because 60% of BCKDH activity
occurs in the muscle. This is enough to permit normal protein intake and prevent
metabolic decompensation under stress (<xref rid="B06" ref-type="bibr">6</xref>).
Mazariegos et al. (<xref rid="B06" ref-type="bibr">6</xref>), in their follow-up study
on transplanted patients for MSUD, mention that six of these patients consented to
donating grafts. The recipients of these grafts had 100% survival and normal BCAA
homeostasis thereafter.</p>
      <p>To our knowledge, there have been no reports of the use of a related donor for MSUD. The
only reported case was an unsuccessful living donor LT, and the recipient died because
of vascular complications. However, the authors did not specify whether the case
involved a heterozygous donor (<xref rid="B06" ref-type="bibr">6</xref>). There are some
concerns about using a related donor. First, based on the inheritance mode of the
disease, parents are most probably obligate heterozygotes and express 50% of BCKDH
activity. Second, theoretically, providing less liver mass with less BCKDH activity
might not prevent metabolic crises under stress (<xref rid="B06" ref-type="bibr">6</xref>). Our study shows that neither the donor nor the recipient experienced
metabolic decompensation after the transplantation. The recipient's leucine levels were
within normal ranges on the second POD, without dietary restrictions. Forty days after
the transplantation, during the treatment for a cytomegalovirus infection, Patient 1 did
not go into metabolic crisis.</p>
      <p>In the evaluation of related living donors for metabolic diseases, the determination of
the donor's heterozygote status is based on the mode of inheritance of each disease.
Depending on the specific deficiency, biochemical assays are carried out for each donor
before deciding to proceed with the transplantation. Morioka et al. (<xref rid="B10" ref-type="bibr">10</xref>) only performed genetic evaluation if biochemical
assays were abnormal for the specific metabolic disease. However, there were no MSUD
cases in their series.</p>
      <p>MSUD is a heterogeneous disease with various phenotypes, including silent types. Silent
phenotypes harbor the mutation and express enough BCKDH activity to prevent the full
clinical phenotype (<xref rid="B01" ref-type="bibr">1</xref>,<xref rid="B11" ref-type="bibr">11</xref>). Although inheritance of MSUD adheres to a simple autosomal
recessive pattern, mutations in each of the three BCKDH-specific genes can cause the
disease (<xref rid="B01" ref-type="bibr">1</xref>). Patients with intermediate and
intermittent types may vary from 2 to 40% of BCKDH activity (<xref rid="B11" ref-type="bibr">11</xref>). Heterozygotes express 50% of BCKDH activity (<xref rid="B12" ref-type="bibr">12</xref>). Usually, this is enough to prevent any
phenotypical expression (<xref rid="B13" ref-type="bibr">13</xref>).</p>
      <p>The mother and the recipient with MSUD were referred to our center after the diagnosis
was established, and we had no information about the mutations. Based on previous family
genetic studies, it was highly probable that the mother would be an obligate
heterozygote (<xref rid="B01" ref-type="bibr">1</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B14" ref-type="bibr">14</xref>). So far, there had been only
one reported case of a mother and child with the intermittent forms of MSUD (<xref rid="B15" ref-type="bibr">15</xref>). However, the genotyping was inconclusive and we
were able to demonstrate the presence of only one pathogenic mutation in the proband and
none in the mother. The mutations presented in Patient 1 are represented in <xref ref-type="fig" rid="f02">Figure 2</xref> and <xref ref-type="table" rid="t01">Table
1</xref>. The heterozygous mutation [c.502C&gt;T (p.R168C)] was already described by
Flaschker et al. (<xref rid="B11" ref-type="bibr">11</xref>) and has been associated
with MSUD in the Human Gene Mutation Database. The homozygous mutation [c.1150G&gt;A
(p.G384S)] was also found by Tsuruta et al. (<xref rid="B16" ref-type="bibr">16</xref>),
but its role in the development of the disease is still under debate. This mutation
could be responsible for creating instability in the protein structure of the enzymatic
complex. However, according to Henneke et al. (<xref rid="B17" ref-type="bibr">17</xref>), this missense mutation (G384S), previously described as pathogenic (<xref rid="B16" ref-type="bibr">16</xref>), can actually represent a polymorphism, because
both MSUD patients studied who carried this homozygous mutation had other pathogenic
mutations in different subunits of the <italic>BCKDH</italic> gene. Also, according to
MutPred version 1.2 (<xref rid="B18" ref-type="bibr">18</xref>), c.502C&gt;T is probably
damaging to protein function and c.1150G&gt;A is probably not protein damaging. Most
likely, the second pathogenic mutation present in the proband of Patient 1, which was
inherited from his mother, is located in some of the noncoding regions of the
<italic>BCKDHB</italic> gene or is an exonic and whole gene-deletion mutation, both
of which are usually not detectable through the strategy used in the present study.
Additional studies will confirm this possibility.</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>DNA sequencing of Patient 1. <italic>A</italic>, Analysis of exon 5 of the
<italic>BCKDHB</italic> gene: base C (blue) was exchanged by T (red) - R168C.
<italic>B</italic>, Analysis of exon 9 of the <italic>DBT</italic> gene: base A
(green) was exchanged by G (black) - G384S.</title>
        </caption>
        <graphic xlink:href="1414-431X-bjmbr-47-06-00522-gf002"/>
      </fig>
      <p>After the introduction of the Modified-PELD allocation system in Brazil in August 2006
(<xref rid="B19" ref-type="bibr">19</xref>), children listed for transplantation
received priority when competing for adult livers. However, the utilization of split LT
is restricted to the use of ideal donors, because good results should be expected for
both recipients. Two problems exist. First, the MSUD recipients receive a lower score
when competing with pediatric patients with end-stage liver disease. Second, the livers
from ideal donors are mainly used in adult patients with fulminant liver failure,
retransplants, high model for end-stage liver disease candidates, and sick pediatric
patients with chronic liver disease. In this scenario, patients with MSUD are at a
disadvantage when competing for livers from the list, and the use of live donors is
justified for patients with metabolic noncirrhotic liver diseases. The safety in using
heterozygous living donors for metabolic diseases was evaluated (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B20" ref-type="bibr">20</xref>), and there was no
difference in survival or incidence of complications when comparing heterozygous with
nonheterozygous donors. No heterozygous donor developed any kind of metabolic
decompensation following the donation. None of the recipients had recurrence of the
original disease after a median follow-up of 7 years (<xref rid="B10" ref-type="bibr">10</xref>).</p>
      <p>In conclusion, our data suggest that the use of a related donor in LT for MSUD was
effective, and the liver of the MSUD patient was successfully used in domino
transplantation. The decision in this case to use a related donor was based both on the
clinical phenotype and the demonstration of normal BCAA levels in the donor. Routine
donor genotyping may not be feasible because the test is not widely available, and, most
importantly, because the disease is associated with both the presence of allelic and
locus heterogeneity. Further studies with this population of patients are required to
expand the use of related donors in MSUD.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank the Nucleus of Research Support (NAP), the Center for Integrative Systems
Biology (CISBi), and University of S&#xE3;o Paulo (USP), Brazil, for their support. Research
supported by the Brazilian Maple Syrup Urine Disorder Network (grant MCT/CNPq/CT-SAUDE
#57/2010).</p>
    </ack>
    <fn-group>
      <fn fn-type="other">
        <p>First published online May 2, 2014.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nellis</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Danner</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Gene preference in maple syrup urine
disease</article-title>
          <source>Am J Hum Genet</source>
          <year>2001</year>
          <volume>68</volume>
          <fpage>232</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="doi">10.1086/316950</pub-id>
          <pub-id pub-id-type="pmid">11112664</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strauss</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Branched-chain ketoacyl dehydrogenase deficiency: maple
syrup disease</article-title>
          <source>Curr Treat Options Neurol</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>329</fpage>
          <lpage>341</lpage>
          <pub-id pub-id-type="doi">10.1007/s11940-003-0039-3</pub-id>
          <pub-id pub-id-type="pmid">12791200</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strauss</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Mazariegos</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Sindhi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Squires</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Finegold</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Vockley</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Elective liver transplantation for the treatment of
classical maple syrup urine disease</article-title>
          <source>Am J Transplant</source>
          <year>2006</year>
          <volume>6</volume>
          <fpage>557</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-6143.2005.01209.x</pub-id>
          <pub-id pub-id-type="pmid">16468966</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Popescu</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dima</surname>
              <given-names>SO</given-names>
            </name>
          </person-group>
          <article-title>Domino liver transplantation: how far can we push the
paradigm?</article-title>
          <source>Liver Transpl</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>22</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1002/lt.22443</pub-id>
          <pub-id pub-id-type="pmid">21987415</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Netter</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Cossarizza</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Narcy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hubert</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ogier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Revillon</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>[Mid-term outcome of 2 cases with maple syrup urine
disease: role of liver transplantation in the treatment]</article-title>
          <source>Arch Pediatr</source>
          <year>1994</year>
          <volume>1</volume>
          <fpage>730</fpage>
          <lpage>734</lpage>
          <pub-id pub-id-type="pmid">7842107</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazariegos</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Sindhi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Soltys</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nayyar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bond</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Liver transplantation for classical maple syrup urine
disease: long-term follow-up in 37 patients and comparative United Network for
Organ Sharing experience</article-title>
          <source>J Pediatr</source>
          <year>2012</year>
          <volume>160</volume>
          <fpage>116</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2011.06.033</pub-id>
          <pub-id pub-id-type="pmid">21839471</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shellmer</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>DeVito</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Dew</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Noll</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Strauss</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cognitive and adaptive functioning after liver
transplantation for maple syrup urine disease: a case series</article-title>
          <source>Pediatr Transplant</source>
          <year>2011</year>
          <volume>15</volume>
          <fpage>58</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1399-3046.2010.01411.x</pub-id>
          <pub-id pub-id-type="pmid">20946191</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chuang</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Chuang</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Wynn</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Lessons from genetic disorders of branched-chain amino
acid metabolism</article-title>
          <source>J Nutr</source>
          <year>2006</year>
          <volume>136</volume>
          <fpage>243S</fpage>
          <lpage>249S</lpage>
          <pub-id pub-id-type="pmid">16365091</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khanna</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nyhan</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Hassanein</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Panyard-Davis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barshop</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Domino liver transplantation in maple syrup urine
disease</article-title>
          <source>Liver Transpl</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>876</fpage>
          <lpage>882</lpage>
          <pub-id pub-id-type="doi">10.1002/lt.20744</pub-id>
          <pub-id pub-id-type="pmid">16628687</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morioka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kasahara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Corrales</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Yoshizawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Living donor liver transplantation for pediatric
patients with inheritable metabolic disorders</article-title>
          <source>Am J Transplant</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>2754</fpage>
          <lpage>2763</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-6143.2005.01084.x</pub-id>
          <pub-id pub-id-type="pmid">16212637</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flaschker</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Feyen</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Fend</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schadewaldt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wendel</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Description of the mutations in 15 subjects with variant
forms of maple syrup urine disease</article-title>
          <source>J Inherit Metab Dis</source>
          <year>2007</year>
          <volume>30</volume>
          <fpage>903</fpage>
          <lpage>909</lpage>
          <pub-id pub-id-type="doi">10.1007/s10545-007-0579-x</pub-id>
          <pub-id pub-id-type="pmid">17922217</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Edenberg</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Crabb</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Evidence for both a regulatory mutation and a structural
mutation in a family with maple syrup urine disease</article-title>
          <source>J Clin Invest</source>
          <year>1989</year>
          <volume>83</volume>
          <fpage>1425</fpage>
          <lpage>1429</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI114033</pub-id>
          <pub-id pub-id-type="pmid">2703538</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McConnell</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Burkholder</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Danner</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Two new mutations in the human E1 beta subunit of
branched chain alpha-ketoacid dehydrogenase associated with maple syrup urine
disease</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1997</year>
          <volume>1361</volume>
          <fpage>263</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="doi">10.1016/S0925-4439(97)00046-X</pub-id>
          <pub-id pub-id-type="pmid">9375800</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chuang</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Ku</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Kerr</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <article-title>Detection of heterozygotes in maple-syrup-urine disease:
measurements of branched-chain alpha-ketoacid dehydrogenase and its components in
cell cultures</article-title>
          <source>Am J Hum Genet</source>
          <year>1982</year>
          <volume>34</volume>
          <fpage>416</fpage>
          <lpage>424</lpage>
          <pub-id pub-id-type="pmid">7081220</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaleski</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Dancis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Hutzler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zaleski</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Variant maple syrup urine disease in mother and
daughter</article-title>
          <source>Can Med Assoc J</source>
          <year>1973</year>
          <volume>109</volume>
          <fpage>299</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="pmid">4730202</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsuruta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mitsubuchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mardy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Miura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hayashida</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kinugasa</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular basis of intermittent maple syrup urine
disease: novel mutations in the E2 gene of the branched-chain alpha-keto acid
dehydrogenase complex</article-title>
          <source>J Hum Genet</source>
          <year>1998</year>
          <volume>43</volume>
          <fpage>91</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="doi">10.1007/s100380050047</pub-id>
          <pub-id pub-id-type="pmid">9621512</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henneke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flaschker</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Helbling</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schadewaldt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gartner</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of twelve novel mutations in patients
with classic and variant forms of maple syrup urine disease</article-title>
          <source>Hum Mutat</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>417</fpage>
          <pub-id pub-id-type="doi">10.1002/humu.9187</pub-id>
          <pub-id pub-id-type="pmid">14517957</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Mort</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Xin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kamati</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>DN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Automated inference of molecular mechanisms of disease
from amino acid substitutions</article-title>
          <source>Bioinformatics</source>
          <year>2009</year>
          <volume>25</volume>
          <fpage>2744</fpage>
          <lpage>2750</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btp528</pub-id>
          <pub-id pub-id-type="pmid">19734154</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neto</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Carone</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pugliese</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Porta</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Miura</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Modified pediatric end-stage liver disease scoring
system and pediatric liver transplantation in Brazil</article-title>
          <source>Liver Transpl</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>426</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="pmid">20213836</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morioka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kasahara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Uryuhara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Living donor liver transplantation for noncirrhotic
inheritable metabolic liver diseases: impact of the use of heterozygous
donors</article-title>
          <source>Transplantation</source>
          <year>2005</year>
          <volume>80</volume>
          <fpage>623</fpage>
          <lpage>628</lpage>
          <pub-id pub-id-type="doi">10.1097/01.tp.0000167995.46778.72</pub-id>
          <pub-id pub-id-type="pmid">16177636</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
